Generic-drug giant Viatris announced on October 8 that it will acquire Pacira BioSciences for $36.50 per share in cash — a $1.65 billion deal that hands it two patent-protected, high-margin pain medicines and moves it closer to becoming what its CEO calls "a leader in non-opioid pain management therapies."
The $36.50 price represents a roughly 44.8% premium to Pacira's $25.20 closing price the day before the announcement. The deal is structured as a tender offer for all outstanding Pacira common shares, followed by a second-step merger at the same price. Both boards have approved it unanimously, and Pacira's board is unanimously recommending that stockholders tender their shares.
Closing is expected by the end of 2026, conditioned on a majority of shares being tendered and the expiration of the regulatory waiting period. Pacira will become a wholly owned subsidiary of Viatris and be delisted from the Nasdaq Global Select Market. Viatris said the transaction is expected to be immediately accretive to its financial guidance metrics.
Viatris plans to fund the acquisition primarily with excess cash, covering the remainder with short-term borrowings, and expects minimal impact on its gross leverage ratio. The structure is "consistent with Viatris' disciplined and balanced approach to capital allocation, preserves our financial flexibility," said Paul Campbell, the company's Interim CFO, Chief Accounting Officer and Corporate Controller.
At the heart of the deal are Pacira's two marketed medicines: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic used for postsurgical pain, and ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an intra-articular injection for osteoarthritis knee pain. Both are high-margin products sold in the United States.
Viatris CEO Scott A. Smith framed the acquisition as positioning the company "as a leader in non-opioid pain management therapies." The portfolio is synergistic with Viatris's own fast-acting meloxicam program for moderate-to-severe acute pain, which faces an FDA target action date of December 27, 2026.
With opioid prescribing under ever-tighter control, non-opioid analgesia has become one of pharma's most contested lanes. Analysts noted that EXPAREL and ZILRETTA give Viatris a plug-and-play commercial pain portfolio rather than a pipeline-only story, and that the roughly 45% premium signals the buyer's confidence in the two products' cash flows.
For Pacira shareholders, it is a high-premium cash exit. For Viatris, it is a $1.65 billion purchase of a ready-made pain franchise.